Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GHSR | Q92847 | 3/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.41 |
| ▸ | LMNA | P02545 | 2/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.40 |
| ▸ | MEN1 | O00255 | 4/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
| ▸ | NPC1 | O15118 | 1/20 | 0.39 |
| ▸ | RAB9A | P51151 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.38 |
| ▸ | HTT | P42858 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL867766 | 1.00 | GHSR (0.51) | GHSRSMN1; SMN2ALDH1A1LMNAMAPK1 | |
| SCHEMBL866629 | 0.91 | GHSR (0.51) | GHSRSMN1; SMN2ALDH1A1LMNAMAPK1 | |
| SCHEMBL7850052 | 0.91 | GHSR (0.51) | GHSRSMN1; SMN2ALDH1A1LMNAMAPK1 | |
| SCHEMBL866628 | 0.91 | GHSR (0.51) | GHSRSMN1; SMN2ALDH1A1LMNAMAPK1 | |
| SCHEMBL867083 | 0.89 | GHSR (0.51) | GHSR | |
| SCHEMBL867082 | 0.89 | GHSR (0.51) | GHSR | |
| SCHEMBL4369760 | 0.88 | GHSR (0.48) | GHSR | |
| SCHEMBL867814 | 0.88 | LMNA (0.43) | SMN1; SMN2ALDH1A1LMNAMAPK1KMT2A | |
| SCHEMBL7856855 | 0.88 | LMNA (0.43) | SMN1; SMN2ALDH1A1LMNAMAPK1KMT2A | |
| SCHEMBL867813 | 0.88 | LMNA (0.43) | SMN1; SMN2ALDH1A1LMNAMAPK1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 36 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1077941-B1 | COMPOUNDS WITH GROWTH HORMONE RELEASING PROPERTIES | NOVO NORDISK AS (DK) | 2009-08-12 | — | — | EP | claimed |
| US-6303620-B1 | USED FOR THERAPY OF MEDICAL DISORDERS RESULTING FROM A DEFICIENCY IN GROWTH HORMONE | NOVO NORDISK A/S (DK) | 2001-10-16 | — | — | US | claimed |
| EP-1077941-A1 | COMPOUNDS WITH GROWTH HORMONE RELEASING PROPERTIES | Novo Nordisk A/S (DK) | 2001-02-28 | — | — | EP | claimed |
| WO-1999058501-A1 | COMPOUNDS WITH GROWTH HORMONE RELEASING PROPERTIES | NOVO NORDISK A/S (DK) | 1999-11-18 | — | — | WO | claimed |
| US-8394833-B2 | Methods of treating emesis using growth hormone secretagogues | HELSINN THERAPEUTICS (U.S.), INC. (US) | 2013-03-12 | — | — | US | disclosed |
| US-8394833-B2 | Methods of treating emesis using growth hormone secretagogues | HELSINN THERAPEUTICS (U.S.), INC. (US) | 2013-03-12 | — | — | US | disclosed |
| US-8288427-B2 | Methods of treating emesis using growth hormone secretagogues | HELSINN THERAPEUTICS (U.S.), INC. (US) | 2012-10-16 | — | — | US | disclosed |
| US-8288427-B2 | Methods of treating emesis using growth hormone secretagogues | HELSINN THERAPEUTICS (U.S.), INC. (US) | 2012-10-16 | — | — | US | disclosed |
| US-20120232113-A1 | METHODS OF TREATING EMESIS USING GROWTH HORMONE SECRETAGOGUES | HELSINN THERAPEUTICS (U.S.), INC. (US) | 2012-09-13 | — | — | US | disclosed |
| US-20120232113-A1 | METHODS OF TREATING EMESIS USING GROWTH HORMONE SECRETAGOGUES | HELSINN THERAPEUTICS (U.S.), INC. (US) | 2012-09-13 | — | — | US | disclosed |
| EP-1789067-B8 | Use of growth hormone secretagogues for stimulating the motility of the gastrointestinal system | HELSINN HEALTHCARE SA (CH) | 2012-08-15 | — | — | EP | disclosed |
| US-20120077745-A1 | Method of stimulating the motility of the gastrointestinal system using growth hormone secretagogues | HELSINN THERAPEUTICS (U.S.), INC. (US) | 2012-03-29 | — | — | US | disclosed |
| EP-1789067-A2 | METHOD OF STIMULATING THE MOTILITY OF THE GASTROINTESTINAL SYSTEM USING GROWTH HORMONE SECRETAGOGUES | Sapphire Therapeutics, Inc. (US) | 2007-05-30 | — | — | EP | disclosed |
| EP-1735055-A1 | METHOD OF REDUCING C-REACTIVE PROTEIN USING GROWTH HORMONE SECRETAGOGUES | Sapphire Therapeutics, Inc. (US) | 2006-12-27 | — | — | EP | disclosed |
| WO-2006020930-A2 | METHOD OF STIMULATING THE MOTILITY OF THE GASTROINTESTINAL SYSTEM USING GROWTH HORMONE SECRETAGOGUES | SAPPHIRE THERAPEUTICS, INC. (US) | 2006-02-23 | — | — | WO | disclosed |
| US-20050261201-A1 | Method of reducing C-reactive protein using growth hormone secretagogues | REJUVENON CORPORATION (US) | 2005-11-24 | — | — | US | disclosed |
| WO-2005097261-A1 | METHOD OF REDUCING C-REACTIVE PROTEIN USING GROWTH HORMONE SECRETAGOGUES | SAPPHIRE THERAPEUTICS, INC. (US) | 2005-10-20 | — | — | WO | disclosed |
| US-6303620-B1 | USED FOR THERAPY OF MEDICAL DISORDERS RESULTING FROM A DEFICIENCY IN GROWTH HORMONE | NOVO NORDISK A/S (DK) | 2001-10-16 | — | — | US | disclosed |
| EP-1077941-A1 | COMPOUNDS WITH GROWTH HORMONE RELEASING PROPERTIES | Novo Nordisk A/S (DK) | 2001-02-28 | — | — | EP | disclosed |
| WO-1999058501-A1 | COMPOUNDS WITH GROWTH HORMONE RELEASING PROPERTIES | NOVO NORDISK A/S (DK) | 1999-11-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050261201-A1 | Method of reducing C-reactive protein using growth hormone secretagogues | CETP, FABP7, TGFB1 | GHSR 14/4885SMN1; SMN2 2034/4885ALDH1A1 1863/4885 |
| US-20120077745-A1 | Method of stimulating the motility of the gastrointestinal system using growth hormone secretagogues | GHSR, GHRHR, MLNR | GHSR 1/4885SMN1; SMN2 1268/4885ALDH1A1 4209/4885 |
| US-20120232113-A1 | METHODS OF TREATING EMESIS USING GROWTH HORMONE SECRETAGOGUES | GHSR, GHRHR, CRH | GHSR 1/4885SMN1; SMN2 2819/4885ALDH1A1 2851/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.